



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Measures

<i>(Dollars in Millions Except Per Share Data)</i>	Second Quarter		% Incr. / (Decr.)	Six Months YTD		% Incr. / (Decr.)
	2011	2010		2011	2010	
Earnings before provision for taxes on income - as reported	\$ 3,422	4,220	(18.9) %	\$ 7,932	10,500	(24.5) %
Restructuring - Cordis	676	-		676	-	
Net Litigation Settlements Loss (Gain)/Other*	315	157		661	(1,340)	
Earnings before provision for taxes on income - as adjusted	<u>\$ 4,413</u>	<u>4,377</u>	<u>0.8 %</u>	<u>\$ 9,269</u>	<u>9,160</u>	<u>1.2 %</u>
Net Earnings - as reported	\$ 2,776	3,449	(19.5) %	\$ 6,252	7,975	(21.6) %
Restructuring - Cordis	549	-		549	-	
Net Litigation Settlements Loss (Gain)/Other*	223	(67)		494	(977)	
Net Earnings - as adjusted	<u>\$ 3,548</u>	<u>3,382</u>	<u>4.9 %</u>	<u>\$ 7,295</u>	<u>6,998</u>	<u>4.2 %</u>
Diluted Net earnings per share - as reported	\$ 1.00	1.23	(18.7) %	\$ 2.25	2.85	(21.1) %
Restructuring - Cordis	0.20	-		0.20	-	
Net Litigation Settlements Loss (Gain)/Other*	0.08	(0.02)		0.18	(0.35)	
Diluted Net earnings per share - as adjusted	<u>\$ 1.28</u>	<u>1.21</u>	<u>5.8 %</u>	<u>\$ 2.63</u>	<u>2.50</u>	<u>5.2 %</u>

* In 2011, Other includes additional DePuy ASR™ Hip recall costs and a mark-to-market gain associated with a currency option related to the planned acquisition of Synthes.

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.